


ACTUALFARMA

Jornadas farmacológicas

Infundimos conocimiento

F. Fonseca ¹, G. Silva¹, N. Landeira ¹ ¹ Hospital Espírito Santo, Évora – E.P.E.


REAL-WORLD EFFECTIVENESS AND SAFETY PROFILE OF TRIFLURIDINE/TIPIRACIL (TAS-102) PLUS BEVACIZUMAB ON COLORECTAL METASTATIC CANCER



ACTUALFARMA

Infundimos conocimiento

OBJETIVES: We aimed to performed a retrospective real-world study to evaluate the effectiveness and toxicity profile of TAS-BEVA association in patients with mCRC.



RESULTS: Eligible population with **CRCm treated with TAS-BEVA, included 8** patients, 62% male, the average age was **66 years old** (48-84), ECOG≤1, **63%** KRAS *wild-type*. Patients was previously treated with 3 prior systemic treatment regimens for advanced disease and were treated in average **4,9 mouths** with **TAS-BEVA**. The population demographic, anthropometric and baseline disease characteristics are summarized on Table 1.




REAL-WORLD EFFECTIVENESS AND SAFETY PROFILE OF TRIFLURIDINE/TIPIRACIL (TAS-102) PLUS BEVACIZUMAB ON COLORECTAL METASTATIC CANCER

Population Characteristics (n = 8)				
Gender –	Female	3 (38%)		
	Male	5 (62%)		
Mean = 66 years-old (48-84)				
Age -	>65 years	4 (50%)		
	<65 years	4 (50%)		
ECOG	PS 0	2 (25%)		
	PS 1	6 (75%)		
> 3 average systemic treatment regimens				
Previous	Anti-VEGF	7 (88%)		
Treatment	Anti-EGFR	1 (12%)		
KRAS	Wild-type	5 (63%)		
Status	Mutated	3 (37%)		

 Table 1: Population Characteristics

Significant survival benefit of TAS-BEVA was observed. A median progression-free survival (PFS) of **5,1 months vs 3,7 and 2,2 months, SUNLIGHT and C-TASK FORCE Trials, respectively**. The comparison between the present study and the Clinical Trials that recommended the therapeutical association TAS-BEVA is represented on **Figure 1**



ACTUALFARMA

Infundimos conocimiento

Figure 1: PFS Clinical Trials vs Present Study

	Present	C-TASK FORCE	SUNLIGHT
	Study	Trial	Trial
Adverse Events Grade>3	73%	72%	69%
Thrombocytopenia Grade <3	50%	12%	5%
Neutropenia Grade ≤3	100%	72%	38%
Neutropenia Grade>4	40%	16%	4%
Leucopenia Grade>3	80%	44%	-
Anemia	60%	16%	18%
<i>b</i>			

REFERENCES:

 Table 2: Security profile of TAS-Bevacizumab

DISCUSSION/CONCLUSIONS: The evaluation of **Real World Data** regarding new therapies is extremely important to guarantee the rational drug use assuring safety and efficacy of innovative therapies or those for which limited literature is available. In this study a higher incidence of **severe Adverse Events** was recorded in comparison to the Clinical Trials that leads to TAS-BEVA recommendation in guidelines. However, this study revealed a clinical benefit of the combined therapy with a median PFS of **5,1 months**, when compared to data described in C-TASK FORCE and SUNLIGHT Trials (3,7 and 2,2, respectively). The aim is to prospectively assess the veracity of the therapeutic superiority described in these trials.

Infundimos conocimiento

